Enovis Co. (NYSE:ENOV) Shares Bought by Comerica Bank

Comerica Bank raised its position in shares of Enovis Co. (NYSE:ENOV - Free Report) by 22.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 49,560 shares of the company's stock after buying an additional 9,224 shares during the quarter. Comerica Bank owned 0.09% of Enovis worth $2,175,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ENOV. Vanguard Group Inc. increased its stake in Enovis by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company's stock valued at $240,731,000 after acquiring an additional 75,348 shares during the period. DAVENPORT & Co LLC lifted its position in Enovis by 6.0% in the 4th quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company's stock valued at $121,181,000 after acquiring an additional 157,216 shares in the last quarter. Royce & Associates LP raised its holdings in shares of Enovis by 2.8% in the fourth quarter. Royce & Associates LP now owns 2,470,576 shares of the company's stock valued at $108,409,000 after purchasing an additional 66,891 shares during the last quarter. River Road Asset Management LLC increased its position in shares of Enovis by 3.8% during the 4th quarter. River Road Asset Management LLC now owns 1,238,357 shares of the company's stock worth $54,339,000 after purchasing an additional 45,762 shares during the last quarter. Finally, Boston Partners increased its position in Enovis by 27.1% during the fourth quarter. Boston Partners now owns 1,048,532 shares of the company's stock worth $46,034,000 after buying an additional 223,816 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company's stock.

Wall Street Analyst Weigh In

ENOV has been the subject of a number of recent analyst reports. Needham & Company LLC cut their target price on Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Canaccord Genuity Group lowered their price objective on shares of Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a research note on Wednesday. Finally, JMP Securities decreased their price objective on Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a report on Friday, May 9th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Enovis presently has a consensus rating of "Moderate Buy" and a consensus price target of $58.00.

Enovis Stock Down 3.1%

ENOV stock traded down $1.16 during midday trading on Wednesday, hitting $36.19. The company's stock had a trading volume of 324,998 shares, compared to its average volume of 774,436. The company has a market cap of $2.07 billion, a PE ratio of -16.53 and a beta of 1.79. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The firm's 50-day moving average is $35.18 and its 200-day moving average is $41.55. Enovis Co. has a 12 month low of $29.32 and a 12 month high of $53.84.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of $0.74 by $0.07. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm had revenue of $558.83 million for the quarter, compared to the consensus estimate of $558.80 million. During the same quarter in the previous year, the firm earned $0.50 earnings per share. The company's quarterly revenue was up 8.2% compared to the same quarter last year. On average, equities research analysts forecast that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.